Screener
BioCryst Pharmaceuticals BCRX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| License and other revenues | $60.05M+822% | $5.01M+187% | —— | —— | $6.52M+224% | |
| ORLADEYO | $158.2M+0.9% | $148.35M+10.5% | $151.68M+22.1% | $159.08M+36.8% | $156.84M+44.8% | |
| Product | $157.51M-3.0% | $151.4M+5.3% | $159.2M+23.1% | $157.74M+35.9% | $162.43M+50.4% |
FAQ
- How does BioCryst Pharmaceuticals break its business down?
- BioCryst Pharmaceuticals (BCRX) reports total revenues by product across 3 parts — License and other revenues, ORLADEYO and Product. Each is extracted from the segment footnotes and tracked over time.
- Where does BioCryst Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioCryst Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
